The Precision Medicine World Conference (PMWC) is an independent and established conference series considered to be the preeminent precision medicine conference that attracts recognized leaders, top global researchers and medical professionals, and innovators across healthcare and biotechnology sectors to showcase practical content that helps close the knowledge gap between different sectors, thereby catalyzing cross-functional fertilization and collaboration. Since 2009, recognized as a vital cornerstone for all constituents of the healthcare and biotechnology community, PMWC provides an exceptional forum for the exchange of information about the latest advances in technology (e.g. DNA sequencing technology), in clinical implementation (e.g. cancer and beyond), research, and in all aspects related to the regulatory and reimbursement sectors.
Fenwick partner Kevin Kabler will be speaking at the IO Intellectual Property session (January 21 at 2pm). This session will review key developments in IP law and their impact on patent strategy with a focus on precision medicine and immuno-oncology. The session will provide background and updates on patent eligibility (Section 101), tradeoffs between eligibility and the ability to effectively sue infringers. In addition, it will discuss legal developments that impact patent strategy for antibody or TCR-based products.